Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GNGenfit S.A. logo

Genfit S.A. (GNFT)

NASDAQ Global Select · Currency in USD
$8.95 ▲ +0.35 (+4.07%)
At close: Mar 9, 9:30 AM ET. Market closed.

Summary

Previous Close
$8.60
Open
$9.00
Day's Range
$8.85 – $9.00
52 Week Range
$2.55 – $10.00
Volume
4,213
Avg. Volume
9,403
Market Cap
$445.68M
Beta (5Y Monthly)
0.87
PE Ratio (TTM)
266.31
EPS (TTM)
$0.03
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$13.00

Profile: Genfit S.A.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
180
CEO
M. Pascal Prigent
Website
genfit.com

Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC). Beyond therapeutics, Genfit is also developing its NIS4 technology, designed to aid in the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis.

Earnings

DateEst.Actual
Sep 22, 2025$1.19-$0.24Miss
May 22, 2025-$0.26-$0.64Miss
Nov 7, 2024$0.33$0.59Beat
May 14, 2024$0.84-$0.17Miss
Sep 20, 2023-$0.32-$0.45Miss
Apr 13, 2023-$0.89-$0.30Beat

Analyst view

Consensus price target
$13.00 ▲ +45.3%
Range $13.00 – $13.00
Rating: Buy
Buy 86% · Hold 0% · Sell 14%

Get free alerts on GNFT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.